Clinics and Departments

Laboratory Services

Lab Dept:

Anatomic Pathology

Test Name:


General Information

Lab Order Codes:



P450 Genotyping

CPT Codes:

81225 – CYP2C19 gene analysis, common variants

Test Includes:

An interpretive report detailing the patient’s 2C19 phenotype and ability to metabolize drugs affected by CYP2C19.


Test Indications:

Primary metabolism of many drugs is performed by cytochrome P450, a group of oxidative/dealkylating enzymes localized in the microsomes of many tissues including the intestines and liver. One of these CYP450 enzymes, CYP2C19, metabolizes a wide variety of drugs including antiulcer drugs such as omeprazole, antiseizure drugs such as mephenytoin, the antimalarial proguanil, and the anziolytic diazepam. It is also partially responsible for metabolizing other drugs such as the beta-blocker proranolol and the antidepressants fluvoxamine and fluoxetine. It is also involved in the activation of the anticoagulant clopidogrel.

CYP2C19 drug metabolism is variable. Some individuals have altered CYP2C19 gene sequences that result in synthesis of enzyme devoid of catalytic activity or in enzyme with diminished catalytic activity. These individuals metabolize clopidogrel, mephenytoin, omeprazole, diazepam, projuanil, and propanolol poorly. A number of specific polymorphisms have been found in the CYP2C19 gene that results in enzymatic deficiencies. The frequency of these polymorphisms varies within the major ethnic groups. CYP2C19 polymorphisms that produce poor metabolizers are found with frequencies of 2% to 5% in Caucasions, 4% in African Americans, 13 to 23% in Asians, and 38% to 79% in Polynesians and Micronesians.

Lab Testing Section:

Anatomic Pathology - Sendouts

Referred to:

Mayo Medical Laboratories (MML Test: 2C19/60439)

Phone Numbers:

MIN Lab: 612-813-6280

STP Lab: 651-220-6550

Test Availability:

Daily, 24 hours

Turnaround Time:

5 - 10 days

Special Instructions:



Specimen Type:

Whole blood


Lavender top tube

Draw Volume:

3 mL (minimum: 0.3 mL) blood

Processed Volume:

Same as Draw Volume


Routine venipuncture

Special Processing:

Lab Staff: Do Not centrifuge. Do Not freeze. Submit specimen in original collection container. Store and ship at room temperature.

Patient Preparation:

Transfusions will interfere with testing. Wait 4-6 weeks post-transfusion to draw. Bone marrow and liver transplants will also interfere with testing.

Sample Rejection:

Mislabeled or unlabeled specimens


Reference Range:

An interpretive report will be provided.

Drug-drug interactions and drug/metabolite inhibition must be considered when dealing with heterozyqous individuals. Drug/metabolite inhibition can occur, resulting in inhibition of residual functional CYP2C19 catalytic activity.

Patients may also develop toxicity problems if liver and kidney functions are impaired.


Direct DNA testing will not detect all known mutations that result in decreased or inactive CYP2C19. Absence of a detectable gene mutation or polymorphism does not rule out the possibility that a patient has an intermediate or poor metabolizer phenotype.

This test detects only the specified polymorphisms. Additional findings, such as small insertions and deletions or novel mutations, will be reported if found. Other polymorphisms in the primer binding regions can affect the testing, and, ultimately, the genotyping assessment made.


Polymerase Chain Reaction (PCR) followed by DNA Sequence Analysis


Mayo Medical Laboratories February 2013

  Lab Test Directory
    Microbiology/ Virology
    Other Fluids
    Transfusion Services

  Search Lab Test Directory
    List All Documents

  Lab Staff

  E-mail Lab Services